S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
S&P 500   4,140.06
DOW   32,832.54
QQQ   320.71
How to Use the MarketBeat Dividend Calculator
Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing (Ad)
Two Appealing Biotech Stocks for Two Distinct investors
Is Tyson Foods A Buy On Post-Earnings Weakness? 
Pfizer buying spree continues with $5.4B hematology deal
Potential Gold Rush For Investors Sparked By USA Vs. China Trade War (Ad)
Nuclear plant in Ukraine is shelled; Rising dangers feared
Is DoorDash Ready To Sprint Higher? 
Closing prices for crude oil, gold and other commodities
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors (Ad)
NASDAQ:KMDA

Kamada - KMDA Stock Forecast, Price & News

$5.28
+0.11 (+2.13%)
(As of 08/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.16
$5.29
50-Day Range
$4.22
$5.28
52-Week Range
$4.22
$6.96
Volume
24,649 shs
Average Volume
33,782 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
KMDA stock logo

About Kamada (NASDAQ:KMDA) Stock

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Wall Street Analyst Weigh In

Several research firms have commented on KMDA. StockNews.com began coverage on Kamada in a research report on Monday, August 1st. They issued a "buy" rating on the stock. TheStreet lowered Kamada from a "c-" rating to a "d" rating in a research report on Monday, June 13th.

Kamada Price Performance

Shares of NASDAQ:KMDA traded up $0.11 during midday trading on Monday, reaching $5.28. 24,649 shares of the company's stock traded hands, compared to its average volume of 24,461. Kamada has a 1 year low of $4.22 and a 1 year high of $6.96. The company has a market cap of $235.07 million, a P/E ratio of -35.20 and a beta of 0.98. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.22 and a current ratio of 2.75. The company has a fifty day simple moving average of $4.70 and a two-hundred day simple moving average of $5.23.

Kamada (NASDAQ:KMDA - Get Rating) last announced its earnings results on Tuesday, May 17th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.07). Kamada had a negative net margin of 6.31% and a negative return on equity of 3.44%. The business had revenue of $28.09 million for the quarter, compared to analysts' expectations of $32.43 million. During the same quarter last year, the business earned $0.06 EPS. Equities analysts predict that Kamada will post -0.07 EPS for the current fiscal year.

Receive KMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter.

KMDA Stock News Headlines

Kamada (NASDAQ:KMDA) Research Coverage Started at StockNews.com
Kamada (NASDAQ:KMDA) Now Covered by Analysts at StockNews.com
Form 6-K KAMADA LTD For: Jun 15 - StreetInsider.com
See More Headlines
Receive KMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter.

KMDA Company Calendar

Last Earnings
5/17/2022
Today
8/09/2022
Next Earnings (Estimated)
8/10/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KMDA
Employees
355
Year Founded
N/A

Profitability

Net Income
$-2,230,000.00
Pretax Margin
-5.95%

Debt

Sales & Book Value

Annual Sales
$103.64 million
Cash Flow
$0.11 per share
Book Value
$3.97 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.98

Key Executives

  • Mr. Amir London (Age 53)
    Chief Exec. Officer
    Comp: $522k
  • Mr. Chaime Orlev (Age 52)
    Chief Financial Officer
    Comp: $331k
  • Mr. Eran Nir (Age 49)
    Chief Operating Officer
    Comp: $322k
  • Ms. Yifat Philip Esq. (Age 45)
    VP of Legal, Gen. Counsel & Corp. Sec.
    Comp: $247k
  • Mr. David Tsur (Age 72)
    Co-Founder & Deputy Chairman
  • Ms. Hanni Neheman (Age 52)
    VP of Marketing & Sales
  • Ms. Ariella Raban (Age 46)
    VP of HR
  • Mr. Jon R. Knight
    VP of US Commercial Operations













KMDA Stock - Frequently Asked Questions

Should I buy or sell Kamada stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KMDA shares.
View KMDA analyst ratings
or view top-rated stocks.

How has Kamada's stock price performed in 2022?

Kamada's stock was trading at $6.58 on January 1st, 2022. Since then, KMDA shares have decreased by 19.8% and is now trading at $5.28.
View the best growth stocks for 2022 here
.

When is Kamada's next earnings date?

Kamada is scheduled to release its next quarterly earnings announcement on Wednesday, August 10th 2022.
View our KMDA earnings forecast
.

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) issued its quarterly earnings data on Tuesday, May, 17th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by $0.07. The biotechnology company earned $28.09 million during the quarter, compared to analysts' expectations of $32.43 million. Kamada had a negative trailing twelve-month return on equity of 3.44% and a negative net margin of 6.31%. During the same period last year, the business earned $0.06 EPS.

What guidance has Kamada issued on next quarter's earnings?

Kamada issued an update on its FY 2022 earnings guidance on Tuesday, June, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $125.00 million-$135.00 million, compared to the consensus revenue estimate of $83.67 million.

What other stocks do shareholders of Kamada own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW).

What is Kamada's stock symbol?

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

Who are Kamada's major shareholders?

Kamada's stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (0.90%) and Meitav Dash Investments Ltd. (0.19%).

How do I buy shares of Kamada?

Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kamada's stock price today?

One share of KMDA stock can currently be purchased for approximately $5.28.

How much money does Kamada make?

Kamada (NASDAQ:KMDA) has a market capitalization of $235.07 million and generates $103.64 million in revenue each year. The biotechnology company earns $-2,230,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis.

How many employees does Kamada have?

Kamada employs 355 workers across the globe.

How can I contact Kamada?

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The official website for the company is www.kamada.com. The biotechnology company can be reached via phone at (728) 940-6472, via email at ir@kamada.com, or via fax at 972-8940-6473.

This page (NASDAQ:KMDA) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.